Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.

Journal of cellular physiology - 1 Jan 2018

Binabaj Maryam Moradi, Bahrami Afsane, ShahidSales Soodabeh, Joodi Marjan, Joudi Mashhad Mona, Hassanian Seyed Mahdi, Anvari Kazem, Avan Amir

Abstract excerpt

The DNA repair protein O6-Methylguanine-DNA methyltransferase (MGMT) is suggested to be associated with resistance to alkylating agents such as Temozolomide which is being used in treatment of patients with glioblastoma (GBM). Therefore, we evaluated the associations between MGMT promoter methylation and prognosis of patients with glioblastoma (GBM). Data were extracted from publications in Embase, PubMed, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Disease-Free Survival

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 28266716
DOI: 10.1002/jcp.25896

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.PMID 28266716Read ↗

Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusSemantic proximity Read ↗

MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational StudySemantic proximity Read ↗

The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma MultiformeSemantic proximity Read ↗

MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challengesSemantic proximity Read ↗

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: A Portuguese multicentre studySemantic proximity Read ↗

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?Semantic proximity Read ↗

O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter MethylationSemantic proximity Read ↗

MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaSemantic proximity Read ↗

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution StudySemantic proximity Read ↗

MGMT Promoter Methylation: Prognostication beyond Treatment ResponseSemantic proximity Read ↗

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter regionSemantic proximity Read ↗

Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.